Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All metformin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMetforminMetformin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Long and Short-term Metformin Consumption as a Potential Therapy to Prevent Complications of COVID-19

Shaseb et al., Advanced Pharmaceutical Bulletin, doi:10.34172/apb.2023.066, IRCT20160310026998N10
Jul 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
0 0.5 1 1.5 2+ Mortality 74% Improvement Relative Risk Ventilation 79% ICU admission 63% Hospitalization time 5% Metformin  Shaseb et al.  LATE TREATMENT  RCT Is late treatment with metformin beneficial for COVID-19? RCT 189 patients in Iran (March - April 2020) Lower ventilation with metformin (p=0.048) c19early.org Shaseb et al., Advanced Pharmaceutical.., Jul 2022 Favors metformin Favors control
Metformin for COVID-19
3rd treatment shown to reduce risk in July 2020
 
*, now known with p < 0.00000000001 from 91 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,200+ studies for 70+ treatments. c19early.org
RCT 189 hospitalized patients showing lower mortality, ICU admission, and intubation with metformin, statistically significant only for intubation. Treatment patients may have also taken metformin prior to admission. Authors note that patients receiving metformin prior to the study were not matched, and diabetes and hyperlipidemia differed between groups.
risk of death, 74.0% lower, OR 0.26, p = 0.06, treatment 85, control 104, RR approximated with OR.
risk of mechanical ventilation, 79.0% lower, OR 0.21, p = 0.048, treatment 85, control 104, RR approximated with OR.
risk of ICU admission, 63.0% lower, OR 0.37, p = 0.07, treatment 85, control 104, RR approximated with OR.
hospitalization time, 5.0% lower, relative time 0.95, p = 0.52, treatment 85, control 104.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shaseb et al., 2 Jul 2022, Randomized Controlled Trial, Iran, peer-reviewed, 26 authors, study period 20 March, 2020 - 5 April, 2020, trial IRCT20160310026998N10. Contact: ghaffarys@tbzmed.ac.ir.
This PaperMetforminAll
Long and Short-term Metformin Consumption as a Potential Therapy to Prevent Complications of COVID-19
Elnaz Shaseb, Saba Ghaffary, Alireza Garjani, Elnaz Zoghi, Nasrin Maleki Dizaji, Somaieh Soltani, Parvin Sarbakhsh, Mohammad Hossein Somi, Parya Valizadeh, Ali Taghizadieh, Masood Faghihdinevari, Mojtaba Varshochi, Behrooz Naghily, Zhinous Bayatmakoo, Parviz Saleh, Sepehr Taghizadeh, Mehdi Haghdoost, Hamid Owaysi, Fatemeh Ravanbakhsh Ghavghani, Mohammad Kazem Tarzamni, Rojin Moradi, Fateme Javan Ali Azar, Saeid Shabestari Khiabani, Ardavan Ghazanchaei, Sana Hamedani, Shahabeddin Hatefi
Advanced Pharmaceutical Bulletin, doi:10.34172/apb.2023.066
The aim of the study is to evaluate the effect of metformin in complication improvement of hospitalized patients with COVID-19. Methods: This was a randomized clinical trial that involved 189 patients with confirmed COVID-19 infection. Patients in the intervention group received metformin-500 mg twice daily. Patients who received metformin before admission were excluded from the control group. Patients who were discharged before taking at least 2000 mg of metformin were excluded from the study. Primary outcomes were vital signs, need for ICU admission, need for intubation, and mortality. Results: Data showed that patients with diabetes with previous metformin in their regimen had lower percentages of ICU admission and death in comparison with patients without diabetes (11.3% vs. 26.1% (P = 0.014) and 4.9% vs. 23.9% (P ≤ 0.001), respectively). Admission time characteristics were the same for both groups except for diabetes and hyperlipidemia, which were significantly different between the two groups. Observations of naproxen consumption on endpoints, duration of hospitalization, and the levels of spO 2 did not show any significant differences between the intervention and the control group. The adjusted OR for intubation in the intervention group versus the control group was 0.21 [95% CI, 0.04-0.99 (P = 0.047)]. Conclusion: In this trial, metformin consumption had no effect on mortality and ICU admission rates in non-diabetic patients. However, metformin improved COVID-19 complications in diabetic patients who had been receiving metformin prior to COVID-19 infection, and it significantly lowered the intubation rates.
Authors' Contribution Competing Interests The authors declare no financial or non-financial conflict of interests. Ethical Approval Full informed consent was obtained from the participants. The study was conducted under the Research Ethics Committee (REC) of Tabriz University of Medical sciences guidelines of good clinical practice under the authorization of the Ministry of Health and Medical Education and the Helsinki Declaration. The presented data are part of the preliminary results of a clinical trial that is registered with the Iranian Registry of Clinical Trials, number IRCT20160310026998N10 and the ethics code of IR.TBZMED. REC.1398.1309.
References
Barron, Bakhai, Kar, Weaver, Bradley et al., Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study, Lancet Diabetes Endocrinol, doi:10.1016/s2213-8587(20)30272-2
Bramante, Buse, Tamaritz, Palacio, Cohen et al., Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity, J Med Virol, doi:10.1002/jmv.26873
Channappanavar, Perlman, Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology, Semin Immunopathol, doi:10.1007/s00281-017-0629-x
El-Arabey, Abdalla, Eltayb, Metformin, ongoing journey with superdrug revolution, Adv Pharm Bull, doi:10.15171/apb.2019.001
Fadini, Morieri, Longato, Avogaro, Prevalence and impact of diabetes among people infected with SARS-CoV-2, J Endocrinol Invest, doi:10.1007/s40618-020-01236-2
Ferrara, Santilli, 'aiuto, Vitiello, Clinical pharmacology aspects in patients treated with TNF inhibitors during SARS-Cov-2 pandemic, Adv Pharm Bull, doi:10.34172/apb.2021.045
Gupta-Wright, Macleod, Barrett, Filson, Corrah et al., False-negative RT-PCR for COVID-19 and a diagnostic risk score: a retrospective cohort study among patients admitted to hospital, BMJ Open, doi:10.1136/bmjopen-2020-047110
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/s0140-6736(20)30183-5
Jiang, Chen, Liu, Yin, Yang et al., Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: a retrospective cohort study, Diabetes Res Clin Pract, doi:10.1016/j.diabres.2020.108619
Kajiwara, Kusaka, Kimura, Yamaguchi, Nanjo et al., Metformin mediates protection against Legionella pneumonia through activation of AMPK and mitochondrial reactive oxygen species, J Immunol, doi:10.4049/jimmunol.1700474
Kow, Hasan, Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: a meta-analysis, J Med Virol, doi:10.1002/jmv.26498
Lalau, Al-Salameh, Hadjadj, Goronflot, Wiernsperger et al., Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19, Diabetes Metab, doi:10.1016/j.diabet.2020.101216
Li, Fan, Lai, Han, Li et al., Coronavirus infections and immune responses, J Med Virol, doi:10.1002/jmv.25685
Liang, Ding, Li, Wang, Kan et al., Association of preadmission metformin use and mortality in patients with sepsis and diabetes mellitus: a systematic review and meta-analysis of cohort studies, Crit Care, doi:10.1186/s13054-019-2346-4
Oh, Song, Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database cohort study, Acta Diabetol, doi:10.1007/s00592-020-01666-7
Rajeshkumar, Yabuuchi, Pai, Maitra, Hidalgo et al., Fatal toxicity of chloroquine or hydroxychloroquine with metformin in mice, bioRxiv, doi:10.1101/2020.03.31.018556v1
Salehi-Pourmehr, Pourfathi, Tarzamni, Ghojazadeh, Naghili et al., Diagnostic value of chest CT in Iranian patients with suspected COVID-19, Caspian J Intern Med, doi:10.22088/cjim.11.0.527
Tian, Jiang, Yao, Nicholson, Li et al., Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis, J Med Virol, doi:10.1002/jmv.26050
Tseng, Metformin decreases risk of tuberculosis infection in type 2 diabetes patients, J Clin Med, doi:10.3390/jcm7090264
Wargny, Potier, Gourdy, Pichelin, Amadou et al., Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study, Diabetologia, doi:10.1007/s00125-020-05351-w
{ 'indexed': {'date-parts': [[2023, 7, 23]], 'date-time': '2023-07-23T04:12:49Z', 'timestamp': 1690085569369}, 'reference-count': 0, 'publisher': 'Maad Rayan Publishing Company', 'issue': '3', 'content-domain': {'domain': ['apb.tbzmed.ac.ir'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2023, 7, 10]]}, 'abstract': '<jats:p>Purpose: The aim of the study is to evaluate the effect of metformin in complication ' 'improvement of hospitalized patients with COVID-19. Methods: This was a randomized clinical ' 'trial that involved 189 patients with confirmed COVID-19 infection. Patients in the ' 'intervention group received metformin-500 mg twice daily. Patients who received metformin ' 'before admission were excluded from the control group. Patients who were discharged before ' 'taking at least 2000 mg of metformin were excluded from the study. Primary outcomes were ' 'vital signs, need for ICU admission, need for intubation, and mortality. Results: Data showed ' 'that patients with diabetes with previous metformin in their regimen had lower percentages of ' 'ICU admission and death in comparison with patients without diabetes (11.3% vs. 26.1% ' '(P=0.014) and 4.9% vs. 23.9% (P≤0.001), respectively). Admission time characteristics were ' 'the same for both groups except for diabetes and hyperlipidemia, which were significantly ' 'different between the two groups. Observations of naproxen consumption on endpoints, duration ' 'of hospitalization, and the levels of spO2 did not show any significant differences between ' 'the intervention and the control group. The adjusted OR for intubation in the intervention ' 'group versus the control group was 0.21 [95% CI, 0.04-0.99 (P=0.047)]. Conclusion: In this ' 'trial, metformin consumption had no effect on mortality and ICU admission rates in ' 'non-diabetic patients. However, metformin improved COVID-19 complications in diabetic ' 'patients who had been receiving metformin prior to COVID-19 infection, and it significantly ' 'lowered the intubation rates. </jats:p>', 'DOI': '10.34172/apb.2023.066', 'type': 'journal-article', 'created': {'date-parts': [[2022, 8, 28]], 'date-time': '2022-08-28T09:10:05Z', 'timestamp': 1661677805000}, 'page': '621-626', 'update-policy': 'http://dx.doi.org/10.34172/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Long and Short-term Metformin Consumption as a Potential Therapy to Prevent Complications of ' 'COVID-19', 'prefix': '10.34172', 'volume': '13', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-7931-4632', 'authenticated-orcid': True, 'given': 'Elnaz', 'family': 'Shaseb', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Pharmacotherapy, Drug Applied Research Center, ' 'Tabriz University of Medical Sciences, Tabriz, Iran.'}, { 'name': 'Faculty of Pharmacy, Tabriz University of Medical Sciences, ' 'Tabriz, Iran.'}]}, { 'ORCID': 'http://orcid.org/0000-0003-1336-6039', 'authenticated-orcid': True, 'given': 'Saba', 'family': 'Ghaffary', 'sequence': 'additional', 'affiliation': [ { 'name': 'Faculty of Pharmacy, Tabriz University of Medical Sciences, ' 'Tabriz, Iran.'}, { 'name': 'Hematology and Oncology Research Center, Tabriz University of ' 'Medical Sciences, Tabriz, Iran.'}]}, { 'given': 'Alireza', 'family': 'Garjani', 'sequence': 'additional', 'affiliation': [ { 'name': 'Faculty of Pharmacy, Tabriz University of Medical Sciences, ' 'Tabriz, Iran.'}]}, { 'given': 'Elnaz', 'family': 'Zoghi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Faculty of Pharmacy, Tehran University of Medical Sciences, ' 'Tabriz, Iran.'}]}, { 'given': 'Nasrin', 'family': 'Maleki Dizaji', 'sequence': 'additional', 'affiliation': [ { 'name': 'Faculty of Pharmacy, Tabriz University of Medical Sciences, ' 'Tabriz, Iran.'}]}, { 'given': 'Somaieh', 'family': 'Soltani', 'sequence': 'additional', 'affiliation': [ { 'name': 'Faculty of Pharmacy, Tabriz University of Medical Sciences, ' 'Tabriz, Iran.'}]}, { 'given': 'Parvin', 'family': 'Sarbakhsh', 'sequence': 'additional', 'affiliation': [ { 'name': 'Road Traffic Injury Research Center, Tabriz University of ' 'Medical Sciences, Tabriz, Iran.'}]}, { 'given': 'Mohammad Hossein', 'family': 'Somi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Liver and Gastrointestinal Disease Research Center, Tabriz ' 'University of Medical Sciences, Tabriz, Iran.'}]}, { 'given': 'Parya', 'family': 'Valizadeh', 'sequence': 'additional', 'affiliation': [ { 'name': 'School of Medicine, Tehran University of Medical Sciences, ' 'Tehran, Iran.'}]}, { 'given': 'Ali', 'family': 'Taghizadieh', 'sequence': 'additional', 'affiliation': [ { 'name': 'Tuberculosis and Lung Diseases Research Center, Tabriz ' 'University of Medical Sciences, Tabriz, Iran.'}]}, { 'given': 'Masood', 'family': 'Faghihdinevari', 'sequence': 'additional', 'affiliation': [ { 'name': 'Liver and Gastrointestinal Disease Research Center, Tabriz ' 'University of Medical Sciences, Tabriz, Iran.'}]}, { 'given': 'Mojtaba', 'family': 'Varshochi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Infectious and Tropical Diseases Research Center, Tabriz ' 'University of Medical Sciences, Tabriz, Iran.'}]}, { 'given': 'Behrooz', 'family': 'Naghily', 'sequence': 'additional', 'affiliation': [ { 'name': 'Infectious and Tropical Diseases Research Center, Tabriz ' 'University of Medical Sciences, Tabriz, Iran.'}]}, { 'given': 'Zhinous', 'family': 'Bayatmakoo', 'sequence': 'additional', 'affiliation': [ { 'name': 'Infectious and Tropical Diseases Research Center, Tabriz ' 'University of Medical Sciences, Tabriz, Iran.'}]}, { 'given': 'Parviz', 'family': 'Saleh', 'sequence': 'additional', 'affiliation': [ { 'name': 'Infectious and Tropical Diseases Research Center, Tabriz ' 'University of Medical Sciences, Tabriz, Iran.'}]}, { 'given': 'Sepehr', 'family': 'Taghizadeh', 'sequence': 'additional', 'affiliation': [ { 'name': 'Infectious and Tropical Diseases Research Center, Tabriz ' 'University of Medical Sciences, Tabriz, Iran.'}]}, { 'given': 'Mehdi', 'family': 'Haghdoost', 'sequence': 'additional', 'affiliation': [ { 'name': 'Infectious and Tropical Diseases Research Center, Tabriz ' 'University of Medical Sciences, Tabriz, Iran.'}]}, { 'given': 'Hamid', 'family': 'Owaysi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Infectious and Tropical Diseases Research Center, Tabriz ' 'University of Medical Sciences, Tabriz, Iran.'}]}, { 'given': 'Fatemeh', 'family': 'Ravanbakhsh Ghavghani', 'sequence': 'additional', 'affiliation': [ { 'name': 'Infectious and Tropical Diseases Research Center, Tabriz ' 'University of Medical Sciences, Tabriz, Iran.'}]}, { 'given': 'Mohammad Kazem', 'family': 'Tarzamni', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Radiology, Medical Radiation Sciences Research ' 'Group, Imam Reza Hospital, Tabriz University of Medical ' 'Sciences, Tabriz, Iran.'}]}, { 'given': 'Rojin', 'family': 'Moradi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Radiology, Medical Radiation Sciences Research ' 'Group, Imam Reza Hospital, Tabriz University of Medical ' 'Sciences, Tabriz, Iran.'}]}, { 'given': 'Fateme', 'family': 'Javan Ali Azar', 'sequence': 'additional', 'affiliation': [ { 'name': 'Faculty of Medicine, Tabriz University of Medical Sciences, ' 'Tabriz, Iran.'}]}, { 'given': 'Saeid', 'family': 'Shabestari Khiabani', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Pharmacotherapy, Drug Applied Research Center, ' 'Tabriz University of Medical Sciences, Tabriz, Iran.'}]}, { 'given': 'Ardavan', 'family': 'Ghazanchaei', 'sequence': 'additional', 'affiliation': [ { 'name': 'Imam Reza Hospital, Tabriz University of Medical Sciences, ' 'Tabriz, Iran.'}]}, { 'given': 'Sana', 'family': 'Hamedani', 'sequence': 'additional', 'affiliation': [ { 'name': 'Faculty of Pharmacy, Tabriz University of Medical Sciences, ' 'Tabriz, Iran.'}]}, { 'given': 'Shahabeddin', 'family': 'Hatefi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Faculty of Pharmacy, Tabriz University of Medical Sciences, ' 'Tabriz, Iran.'}]}], 'member': '20123', 'published-online': {'date-parts': [[2022, 7, 2]]}, 'container-title': 'Advanced Pharmaceutical Bulletin', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://apb.tbzmed.ac.ir/PDF/apb-13-621.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://apb.tbzmed.ac.ir/PDF/apb-13-621.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 7, 22]], 'date-time': '2023-07-22T06:11:13Z', 'timestamp': 1690006273000}, 'score': 1, 'resource': {'primary': {'URL': 'https://apb.tbzmed.ac.ir/Article/apb-33452'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 7, 2]]}, 'references-count': 0, 'journal-issue': { 'issue': '3', 'published-online': {'date-parts': [[2023, 7, 10]]}, 'published-print': {'date-parts': [[2023, 7, 10]]}}, 'URL': 'http://dx.doi.org/10.34172/apb.2023.066', 'relation': {}, 'ISSN': ['2228-5881', '2251-7308'], 'subject': ['General Pharmacology, Toxicology and Pharmaceutics', 'Pharmaceutical Science'], 'container-title-short': 'Adv Pharm Bull', 'published': {'date-parts': [[2022, 7, 2]]}, 'assertion': [ { 'value': 'Tabriz University of Medical Sciences', 'name': 'journal_owner', 'label': 'Journal Owner'}, { 'value': 'Tabriz University of Medical Sciences', 'name': 'journal_publisher', 'label': 'Journal Publisher'}, { 'value': '2021-12-13', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2022-07-01', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2022-07-02', 'order': 3, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit